At NEVNUCLAB, we are redefining the future of nuclear medicine by accelerating access to next-generation medical isotopes through a scalable, outsourced, and regulation-ready model. Founded in 2023, we partner with leading public labs to identify, produce, and deliver critical isotopes like Actinium-225 and Copper-67 to hospitals, research institutions, and pharmaceutical companies worldwide.